Abstract:PD-(L)1 inhibitors have provided new treatment approaches for patients with NSCLC; however, resistance to PD-(L)1 inhibitors or low PD-L1 expression may limit clinical benefit. Tislelizumab, a monoclonal antibody with high affinity and specificity for PD-1, was recently approved in China for the treatment of previously treated classical Hodgkin lymphoma. Tislelizumab was engineered to minimize binding to FcɣR on macrophages to abrogate antibody-dependent phagocytosis, a mechanism of T-cell clearance and potential resistance to anti- PD-1 therapy. Preliminary reports from this study (NCT04068519) showed that tislelizumab monotherapy was generally well tolerated and demonstrated antitumor activity in Chinese patients with advanced solid tumors. We now present data from patients with NSCLC. This multi-arm, open-label, nonrandomized phase 1/2 study evaluated safety/tolerability, antitumor activity, and survival in patients with histologically/cytologically confirmed advanced solid tumors treated with tislelizumab. Eligible patients progressed on, or were intolerant to, their last standard antitumor treatment and were anti-PD-(L)1 therapy treatment-naïve. Patients received intravenous tislelizumab 200 mg every 3 weeks until loss of clinical benefit or unacceptable toxicity. Patients were considered PD-L1-positive if ≥10% of their tumor cells had PD-L1 membrane staining at any intensity using the VENTANA PD-L1 (SP263) assay. Antitumor response was assessed by RECIST v1.1, overall survival (OS) was estimated by Kaplan-Meier analysis, and safety/tolerability was examined by monitoring adverse events (AEs). As of 01 December 2018, 56 patients with NSCLC (nonsquamous, n=31 [55%]; squamous, n=25 [45%]) were enrolled. Forty patients (71%) were male, 53 (95%) had metastatic disease, and 23 (41%) had never smoked; one patient each had an EGFR mutation or ALK rearrangement. Patients were heavily pretreated, with 16 patients (29%) receiving ≥3 lines of prior systemic therapy. The most common treatment-related AEs (TRAEs) were increased AST (n=14; 25%), increased ALT (n=13; 23%), and rash (n=8; 14%). Increased AST (n=3; 5%) and increased ALT (n=2; 4%) were the only grade ≥3 TRAEs occurring in ≥2 patients. Immune-related AEs (irAE) were reported in 12 patients (21%) and were generally of low severity, including 1 patient with grade 2 pneumonitis; 4 patients (7%) experienced a grade ≥3 irAE. The objective response rate (ORR) was 18% (95% CI: 8.9, 30.4), with an ORR of 17% (95% CI: 4.7, 37.4) and 19% (95% CI: 7.5, 37.5) in patients who were PD-L1-positive (n=24) and PD-L1-negative (n=31), respectively. With a median follow-up of 14.6 months (95% CI: 12.0, 15.6), median OS was not reached in patients with NSCLC. Updated data with a follow-up of ≥2 years will be presented, including OS. Tislelizumab was generally well tolerated and demonstrated antitumor activity in NSCLC patients regardless of PD-L1 expression status. Tislelizumab is being evaluated as a single agent or with chemotherapy in phase 3 studies in NSCLC patients (NCT03358875, NCT03594747, and NCT03663205).

Efficacy and Safety of the Anti-PD-L1 Monoclonal Antibody Socazolimab for Recurrent or Metastatic Cervical Cancer: A Phase I Dose-Escalation and Expansion Study

Efficacy and safety of the anti–PD-L1 monoclonal antibody socazolimab for recurrent or metastatic cervical cancer: Results from the phase I dose-escalation and expansion study.

Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study

Phase Ib Study of Sintilimab in Combination with Chemotherapy for 1L Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC).

357 GLS-010 (zimberelimab), a Novel Fully Human Anti-Pd-1 Mab in Chinese Patients with Recurrent/metastatic Cervical Cancer: Results from a Multicenter, Open-Label, Single-Arm Phase II Trial

Results of a phase III clinical trial with anti-PDL1 treatment in combination with chemotherapy for extensive stage small cell lung cancer.

Effect of Human Hydrosalpinx Fluid on in Vitro Mouse Embryogenesis.

Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma.

Assessment of TMB, PD-L1, and lymphocyte to monocyte ratio as predictive potential in a phase Ib study of sintilimab in patients with advanced solid tumors

Efficacy and Safety of Sintilimab in Combination with XELOX in First-Line Gastric or Gastroesophageal Junction Carcinoma (GC/GEJC)

Preliminary Results of a Phase 1/2, First-in-human, Open-Label, Dose Escalation Study of ZL-1211 (Anti-Claudin 18.2 Mab) in Patients with Unresectable or Metastatic Solid Tumors

Efficacy and Safety of PD-L1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: A Retrospective Real-World Study.

Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial

Efficacy and safety of sintilimab plus albumin-bound-paclitaxel in recurrent or metastatic cervical cancer: a multicenter, open-label, single-arm, phase II trial

Efficacy and safety of enlonstobart (SG001), a PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer: A multicenter, single-arm, open-label, phase II study.

Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1–Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial

Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1–positive advanced cervical cancer: a phase II, single-arm study

Early salvage therapy with anti-PD-1 antibody Camrelizumab in patients with advanced cervical cancer: a retrospective study

Efficacy and safety of cadonilimab, an anti-PD-1/CTLA4 bi-specific antibody, in previously treated recurrent or metastatic (R/M) cervical cancer: a multicenter, open-label, single-arm, phase II trial (075)

TS01.03 Efficacy and Safety Data from a Phase 1/2 Trial of Tislelizumab in Chinese Patients with Non-Small Cell Lung Cancer (NSCLC)